Oculis Holding AG
OCS Nasdaq Pharmaceutical Preparations Financials FY2020โFY2025
Revenue
Total sales reported in the income statement.
$1.4M
85.2%
vs prior year
Operating margin
Operating income as a share of revenue.
โ6,811.8%
3,859.9ย pts
Net income
Profit after all expenses, interest and tax.
โ$119M
Free cash flow
Cash from operations minus capital spending.
โ$80.1M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
โ
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$2.27 EPS (TTM)
What Oculis Holding AG does
No business description yet.
- Legal name
- Oculis Holding AG
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Mar 4, 2026
- Accession ยท CIK
- 0001193125-26-091446
0001953530
Revenue and margins
Oculis Holding AG had $1.4M of revenue in fiscal 2025, up 85.2% on the year before.
FY20
Revenue $1.1M
FY21
Revenue $1.1M
FY22
Revenue $1.0M
FY23
Revenue $1.0M
FY24
Revenue $0.8M
FY25
Revenue $1.4M
Q2 '23
Revenue $0.3M
Q2 '24
Revenue $0.3M
Q2 '25
Revenue $0.3M
FY20
Gross โ
Operating โ1,242.3%
Net โ1,497.8%
FCF โ1,213.3%
FY21
Gross โ
Operating โ1,378.3%
Net โ1,932.5%
FCF โ1,443.0%
FY22
Gross โ
Operating โ3,549.9%
Net โ4,243.0%
FCF โ2,756.4%
FY23
Gross โ
Operating โ9,140.9%
Net โ10,056.8%
FCF โ6,238.4%
FY24
Gross โ
Operating โ10,671.6%
Net โ12,504.5%
FCF โ7,164.9%
FY25
Gross โ
Operating โ6,811.8%
Net โ8,253.4%
FCF โ5,555.1%
Gross
Operating
Net
FCF
Q2 '23
Gross โ
Operating โ4,298.3%
Net โ5,151.2%
FCF โ
Q2 '24
Gross โ
Operating โ9,176.9%
Net โ8,505.1%
FCF โ
Q2 '25
Gross โ
Operating โ7,956.0%
Net โ9,720.9%
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$15.8M
FY21
Net income โ$20.3M
FY22
Net income โ$40.5M
FY23
Net income โ$98.8M
FY24
Net income โ$97.4M
FY25
Net income โ$119M
Q2 '23
Net income โ$14.3M
Q2 '24
Net income โ$23.0M
Q2 '25
Net income โ$30.7M
FY20
Diluted EPS โ$6.15
FY21
Diluted EPS โ$6.39
FY22
Diluted EPS โ$11.85
FY23
Diluted EPS โ$3.31
FY24
Diluted EPS โ$2.41
FY25
Diluted EPS โ$2.27
Q2 '23
Diluted EPS โ$0.42
Q2 '24
Diluted EPS โ$0.56
Q2 '25
Diluted EPS โ$0.59
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ
Return on assets โ
FY21
Return on capital โ
Return on equity โ
Return on assets โ31.9%
FY22
Return on capital โ
Return on equity โ
Return on assets โ78.1%
FY23
Return on capital โ
Return on equity โ3,465.1%
Return on assets โ111.9%
FY24
Return on capital โ
Return on equity โ101.0%
Return on assets โ72.3%
FY25
Return on capital โ
Return on equity โ72.5%
Return on assets โ55.3%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$80.1M in fiscal 2025, โ5,555.1% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$12.8M
FY21
Free cash flow โ$15.2M
FY22
Free cash flow โ$26.3M
FY23
Free cash flow โ$61.3M
FY24
Free cash flow โ$55.8M
FY25
Free cash flow โ$80.1M
FY20
Cash from operations โ$12.8M
Capital spending $0.0M
FY21
Cash from operations โ$15.1M
Capital spending $0.0M
FY22
Cash from operations โ$26.3M
Capital spending $0.1M
FY23
Cash from operations โ$61.3M
Capital spending $0.1M
FY24
Cash from operations โ$55.6M
Capital spending $0.3M
FY25
Cash from operations โ$79.8M
Capital spending $0.4M
Cash from operations
Capital spending
Dividends, buybacks and share count
Oculis Holding AG returned โ to shareholders in fiscal 2025. The diluted share count rose 29.3%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.03B
FY24
Diluted shares 0.04B
FY25
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably Oculis Holding AG can carry it.
FY20
Cash $5.6M
Debt โ
FY21
Cash $50.7M
Debt โ
FY22
Cash $21.4M
Debt โ
FY23
Cash $45.7M
Debt โ
FY24
Cash $30.6M
Debt โ
FY25
Cash $103M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $50.7M | $21.4M | $45.7M | $30.6M | $103M |
| Interest coverage | โ176.3x | โ600.0x | โ61.4x | โ114.6x | โ98.0x |
| Current ratio | 11.8x | 2.0x | 5.3x | 2.4x | 6.0x |
| Quick ratio | 11.8x | 2.0x | 5.3x | 2.4x | 6.0x |
| Total assets | $63.6M | $40.1M | $136M | $133M | $298M |
| Total liabilities | $130M | $146M | $24.6M | $51.8M | $50.3M |
| Shareholders' equity | โ$66.8M | โ$106M | $112M | $81.0M | $247M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | 2 / 7 | 3 / 7 | 1 / 7 | 3 / 7 |
| Accruals ratio | โ | โ8.1% | โ27.5% | โ42.6% | โ31.1% | โ18.2% |
| Altman Z'' | โ | โ1.16 | โ14.14 | โ0.65 | โ6.99 | 2.69 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $1.1M | $1.1M | $1.0M | $1.0M | $0.8M | $1.4M |
| Net interest income | $0.0M | $0.0M | $0.1M | โ | โ | โ |
| Research and development | $9.9M | $10.5M | $23.3M | $32.6M | $59.1M | $68.7M |
| Operating income | โ$13.1M | โ$14.5M | โ$33.9M | โ$89.8M | โ$83.1M | โ$98.3M |
| Interest expense | $0.0M | $0.1M | $0.1M | $1.5M | $0.7M | $1.0M |
| Pretax income | โ$15.8M | โ$20.3M | โ$40.5M | โ$98.7M | โ$97.6M | โ$119M |
| Income tax | $0.1M | $0.0M | $0.1M | $0.1M | โ$0.2M | โ$0.2M |
| Net income | โ$15.8M | โ$20.3M | โ$40.5M | โ$98.8M | โ$97.4M | โ$119M |
| Diluted EPS | โ$6.15 | โ$6.39 | โ$11.85 | โ$3.31 | โ$2.41 | โ$2.27 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.03B | 0.04B | 0.05B |
| Cash flow | ||||||
| Cash from operations | โ$12.8M | โ$15.1M | โ$26.3M | โ$61.3M | โ$55.6M | โ$79.8M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.1M | $0.3M | $0.4M |
| Free cash flow | โ$12.8M | โ$15.2M | โ$26.3M | โ$61.3M | โ$55.8M | โ$80.1M |
| Stock-based compensation | $0.3M | $0.4M | $0.8M | $4.0M | $11.1M | $19.3M |
| Balance sheet | ||||||
| Cash and short-term investments | $5.6M | $50.7M | $21.4M | $45.7M | $30.6M | $103M |
| Current assets | โ | $52.6M | $25.6M | $121M | $116M | $276M |
| Current liabilities | โ | $4.5M | $13.0M | $22.8M | $48.8M | $46.4M |
| Property and equipment, net | โ | $0.5M | $0.4M | $0.3M | $0.4M | $0.7M |
| Intangible assets | $9.9M | $9.6M | $13.2M | $14.6M | $14.7M | $16.8M |
| Total assets | โ | $63.6M | $40.1M | $136M | $133M | $298M |
| Total liabilities | โ | $130M | $146M | $24.6M | $51.8M | $50.3M |
| Shareholders' equity | โ$49.6M | โ$66.8M | โ$106M | $112M | $81.0M | $247M |
| Margins | ||||||
| Operating margin | โ1,242.3% | โ1,378.3% | โ3,549.9% | โ9,140.9% | โ10,671.6% | โ6,811.8% |
| Net margin | โ1,497.8% | โ1,932.5% | โ4,243.0% | โ10,056.8% | โ12,504.5% | โ8,253.4% |
| FCF margin | โ1,213.3% | โ1,443.0% | โ2,756.4% | โ6,238.4% | โ7,164.9% | โ5,555.1% |
| Net interest share of revenue | 1.0% | 2.2% | 13.8% | โ | โ | โ |
| Returns | ||||||
| Return on capital employed | โ | โ24.5% | โ125.0% | โ79.0% | โ98.9% | โ39.1% |
| Return on equity | โ | โ | โ | โ3,465.1% | โ101.0% | โ72.5% |
| Return on assets | โ | โ31.9% | โ78.1% | โ111.9% | โ72.3% | โ55.3% |
| Return on tangible equity | โ | โ | โ | โ101.6% | โ146.9% | โ51.6% |
| Growth | ||||||
| Revenue growth | โ | โ0.7% | โ9.1% | 2.9% | โ20.7% | 85.2% |
| Share count change | โ | 7.7% | 7.6% | 900.2% | 35.1% | 29.3% |
| Financial health | ||||||
| Interest coverage | โ684.4x | โ176.3x | โ600.0x | โ61.4x | โ114.6x | โ98.0x |
| Current ratio | โ | 11.8x | 2.0x | 5.3x | 2.4x | 6.0x |
| Quick ratio | โ | 11.8x | 2.0x | 5.3x | 2.4x | 6.0x |
| Capital allocation | ||||||
| Capex / revenue | 1.9% | 2.9% | 7.1% | 5.4% | 33.5% | 25.1% |
| Stock comp / revenue | 33.0% | 34.2% | 88.2% | 408.6% | 1,426.0% | 1,338.1% |
| Quality scores | ||||||
| Piotroski F-score | โ | โ | 2.0 | 3.0 | 1.0 | 3.0 |
| Altman Z'' | โ | โ1.2 | โ14.1 | โ0.6 | โ7.0 | 2.7 |
| Accruals ratio | โ | โ8.1% | โ27.5% | โ42.6% | โ31.1% | โ18.2% |
Source: SEC EDGAR XBRL filings (CIK 0001953530). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CHF under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only โ not investment advice. Check the original filings before relying on any figure.